News

Filter

Current filters:

Oxford BioTherapeutics

First human study under $1 billion Menarini and Oxford BioTherapeutics oncology alliance

25-11-2014

UK biotech firm Oxford BioTherapeutics and Berlin Chemie/Menarini Biotech/Menarini Ricerche (belonging…

Berlin Chemie/Menarini GroupBiotechnologyMenariniOBT357OncologyOxford BioTherapeuticsResearch

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

02-10-2014

UK biotech firm Oxford BioTherapeutics and family-owned Italian Berlin Chemie/Menarini Group have designated…

BiotechnologyItalyMenariniOncologyOxford BioTherapeuticsResearchUK

Oxford BioTherapeutics appoints Eugen Leo as head of clinical development

Oxford BioTherapeutics appoints Eugen Leo as head of clinical development

11-07-2014

UK-based biotech company Oxford BioTherapeutics, focusing on antibody-drug conjugates in the treatment…

BiotechnologyBoardroomOxford BioTherapeuticsUK

Oxford BioTherapeutics uses Amgen’s Xenomouse antibodies for breast cancer

07-05-2014

UK biotech company Oxford BioTherapeutics has obtained the exclusive global rights to USA-based Amgen’s…

AmgenBiotechnologyImmunoGenLicensingOncologyOxford BioTherapeutics

Oxford BioTherapeutics and Menarini progress enhanced antibody for acute myeloid leukemia

09-12-2013

UK-based Oxford BioTherapeutics and Berlin-Chemie, a subsidiary of family-owned Italian drugmaker Menarini,…

BiotechnologyEuropeMenariniOncologyOxford BioTherapeuticsResearch

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

29-04-2013

The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

Menarini in $1 billion partnership with Oxford BioTherapeutics for cancer drug development

29-10-2012

In a second major deal within just over a year for the UK-based antibody-based drug developer, BioTherapeutics…

BiotechnologyLicensingMenariniOncologyOxford BioTherapeuticsPharmaceuticalResearch

Sanofi-Aventis in-licenses Oxford BioTherapeutics antibody for the treatment of solid cancers

25-01-2011

Privately-held, UK-based Oxford BioTherapeutics (OBT) said this morning that French drug major Sanofi-Aventis…

LicensingOncologyOxford BioTherapeuticsPharmaceuticalSanofi-Aventis

COMPANY SPOTLIGHT

Menarini

Back to top